Pfizer Presents Overall Survival Data From PALOMA-3 Trial of IBRANCE (palbociclib)
Pfizer Inc. announced detailed overall survival (OS) data from the PALOMA-3 trial, which evaluated IBRANCE (palbociclib) in combination with fulvestrant compared to placebo plus…
Read More...
Read More...
